Gold prices slid below $4,000/oz amid profit-taking on Gaza ceasefire
Reprogrammed Interchange LLC and Reid Hoffman, both listed as ten percent owners of Vor Biopharma Inc (NASDAQ:VOR), have sold a combined total of 1,407,628 shares of common stock over three days, according to a Form 4 filing with the Securities and Exchange Commission. The sales, which occurred between September 3 and September 5, 2025, generated $2.77 million. The clinical-stage biotech company, currently valued at $249 million, has seen its stock surge over 137% in the past year.
The transactions involved the sale of Vor Biopharma Inc. common stock at prices ranging from $1.9285 to $1.9961. On September 3, 554,612 shares were sold. On September 4, 453,016 shares were sold, and on September 5, 400,000 shares were sold. According to InvestingPro, the stock has demonstrated significant volatility, trading between $0.13 and $3.29 over the past 52 weeks, with 12 additional key insights available to subscribers.
Following these transactions, Reprogrammed Interchange LLC still holds 35,476,939 shares of Vor Biopharma Inc. The company maintains a healthy liquidity position with a current ratio of 3.49, indicating strong short-term financial stability.
In other recent news, Vor Biopharma Inc. reported significant developments, starting with the achievement of a primary endpoint in a Phase 3 clinical trial for telitacicept, conducted by its collaborator RemeGen Co., Ltd. The study, focused on adults with IgA nephropathy in China, showed a 55% reduction in the 24-hour urine protein-to-creatinine ratio at 39 weeks compared to placebo. Additionally, Vor Biopharma shareholders approved changes to the company’s 2021 Equity Incentive Plan, increasing the number of shares reserved for issuance by 25 million and adjusting the annual automatic increase in the share reserve. The company also announced board changes, with the resignation of three directors and the appointment of two new industry veterans, Alexander Cumbo and Michel Detheux, effective July 2025. These appointments bring extensive commercial and executive experience to the board. These recent developments reflect ongoing strategic adjustments and advancements in Vor Biopharma’s operations and collaborations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.